Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-06-05
2010-10-05
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C530S300000, C530S314000, C530S327000, C530S328000
Reexamination Certificate
active
07807629
ABSTRACT:
The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B2receptor agonist to a patient in need thereof.
REFERENCES:
patent: 5750646 (1998-05-01), Coy et al.
patent: 6015818 (2000-01-01), Oku et al.
patent: 6127389 (2000-10-01), Oku et al.
patent: 6288036 (2001-09-01), Kyle et al.
patent: 6316413 (2001-11-01), Dodey et al.
patent: 6358949 (2002-03-01), DeSimone et al.
patent: 6420365 (2002-07-01), Peterson et al.
patent: 6500831 (2002-12-01), Sharif
patent: 6509366 (2003-01-01), Rachwal et al.
patent: 6958349 (2005-10-01), Carson et al.
patent: 2005/0244461 (2005-11-01), Nivaggioli et al.
patent: WO/2003/092584 (2003-11-01), None
Bhoola et al., “Bioregulation of kinins: kallikreins, kininogens, and kininases”, Pharmacol. Rev. vol. 44, 1080, 1992.
Boels and Schaller, “Identification and characterization of GPR100 as a novel human G-protein-coupled bradykinin receptor”, Br. J. Pharmacol. vol. 140 pp. 932-938, 2003.
Chiang et al., “Effects of intravenous infusions of histamine 5-hydroxytryptamine, bradykinin and prostaglandins on intraocular pressure” Arch. Int. Pharmacodyn. Ther. vol. 207 pp. 131-138, 1974.
Cole and Ungar, “Action of bradykinin on intraocular pressure pupillary diameter”, Ophthalmic Res. vol. 6 pp. 308-314, 1974.
Amblard, et al.; “Design and Synthesis of Potent Bradykinin Agonists Containing a Benzothiazepine Moiety”; J. MEd. Chem.; vol. 42; pp. 4185-4192; 1999.
Funk et al., “Intraocular pressure and systemic blood pressure after administration of vasoactive substances in hypertensive and normal rats” Graefes Arch. Clin. Exp. Ophthalmol. vol. 223 pp. 145-149, 1985.
Gibbs et al., “Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeinal nociceptors via activation of the Y1 and Y2 receptors”, Br. J. Pharmacol. vol. 150, pp. 72-79, 2007.
Greco et al., “Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I” Can. J. Physiol. Pharmacol., vol. 84, pp. 1163-1175, 2006.
Green and Elijah, “Drug effects on aqueous humor formation and pseudofacility in normal rabbit eyes” Exp. Eye Res. vol. 33, pp. 239-245, 1981.
Drube & Liebmann; “In various tumour cell lines the peptide bradykinin B2 receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist”; British Journal of Pharmacology; vol. 131; pp. 1553-1560; 2000.
Heitsch, “The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease”, Expert Opinion, Invest. Drugs, vol. 12 pp. 759-770, 2003.
Huang et al., “Modulation by bradykinin of angiotensin type 1 receptor-evoked RhoA activation of connective tissue growth factor expression in human lung fibroblasts”, Am. J. Physiol. Lung Cell Mol. Physiol. vol. 290 pp. L1291-L1299, 2006.
Ito et al. “Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats”, Br. J. Pharmacol. vol. 138, pp. 225-233, 2003.
Kaufman et al. “Effect of serotonin, histamine and bradykinin on outflow facility following ciliary muscle retrodisplacement in the cynomolgus monkey”, Exp. Eye Res. vol. 35 pp. 191-199, 1982.
Feletou, et al.; “Agonistic and antagonistic properties of the bradykinin B2 receptor antagonist, HOE 140, in isolated blood vessels from different species”; British Journal Pharmacology; vol. 112; pp. 683-689; 1994.
Lai et al. “Bombinakinin M gene associated peptide, a novel bioactive peptide from skin secretions of the toadBombina maxima”, Peptides, vol. 24 pp. 199-204, 2003.
Lai et al., “A novel bradykinin-related peptide from skin secretions of toadBombina maximaand its precursor containing six identical copies of the final product”, Biochem. Biophys. Res. Comm. vol. 286 pp. 259, 2001.
Lai et al., “Dynorphin A activates bradykinin receptors to maintain neuropathic pain”, Nature Neurosci. vol. 9 pp. 1534-1540 2006.
Lee et al., “Cloning of bradykinin precursor cDNAs from skin ofBombina maximareveals novel bombinakinin M antagonists and a bradykinin potential peptide”, Regul. Peptides, vol. 127 pp. 207, 2005.
Llobet et al., “Bradykinin decreases outflow facility in perfused anterior segments and induces shape changes in passaged BTM cells in vitro”, Invest. Ophthalmol. Vis. Res., vol. 40 pp. 113-125, 1999.
Ma et al., “Expression and cellular localization of the kallikrein-kinin system in human ocular tissues”, Exp. Eye Res. vol. 63 pp. 19-26, 1996.
Heitsch; “Non-peptide antagonist and agonists of the Bradykinin B2 receptor”; Current Medicinal Chemistry; vol. 9; pp. 913-928; 2002.
Majima et al., “A nonpeptide mimic of bradykinin blunts the development of hypertension in young spontaneously hypertensive rats”, Hypertension vol. 35 pp. 437-442, 2000.
Noda et al., “Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia”, J. Neurochem. vol. 101, pp. 397-410 2007.
O'Rouke et al., “The smooth muscle pharmacology of maximakinin, a receptor-selective, bradykinin-related nonadecapeptide from the venom of the Chinese toad,Bombina maxima”, Regul. Peptides vol. 121 pp. 65, 2004.
Regoli, D. and Barabe, “Pharmacology of bradykinin and related kinins”, J. Pharmacol. Rev., vol. 32, No. 1, pp. 1-46, 1980.
Schroder et al. “Cloning and functional characterizatioan of the ornithokinin receptor” J. Biol. Chem. vol. 272 pp. 12475-12481, 1997.
Sharif et al. “Human trabecular meshwork cells express functional serotonin-2A (5HT2A) receptors: role in IOP reduction”, Invest. Ophthalmol. Vis. Res. vol. 47 pp. 4001-4010, 2006.
Howl & Payne; “Bradykinin receptors as a therapeutic target”; Expert Opinion Ther. Targets; vol. 7; No. 2; pp. 277-285; 2003.
Tamaki et al., “Effect of topical betaxolol on tissue circulation in the human optic nerve head” J. Ocular Pharmacol. Ther. vol. 15 pp. 313-321, 1999.
Marie, et al.; “Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI”; Molecular Pharmacology; vol. 1; pp. 92-101; 1999.
Waki et al., “Reduction of intraocular pressure by topical administration of an inhibitor of the rho-associated protein kinase” Curr. Eye Res. vol. 22 pp. 470-474, 2001.
Tarasevicience-Stewart; Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy; Peptides; vol. 26; pp. 1292-1300; 2005.
Yokahama et al., “Implication of polymodal receptor activities in intraocular pressure elevation by neurogenic inflammation” Jpn. J. Ophthalomol. vol. 34 pp. 245-255, 1990.
Langlois, et al.; “Development of agonists of endothelin-1 exhibition selectivity towards ETa receptors”; British Journal of Pharmacology; vol. 139; pp. 616-622; 2003.
Alcon Research, Ltd.
Derry Jason J.
Kemmerer Elizabeth C.
LandOfFree
Use of bradykinin and related B 2 R agonists to treat ocular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of bradykinin and related B 2 R agonists to treat ocular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bradykinin and related B 2 R agonists to treat ocular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4191448